Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.69 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 3/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428716 | 0.89 | NR4A2 (0.63) | MRGPRX4PTGER1NR4A2LMNAMAPK1 | |
| SCHEMBL4423348 | 0.88 | NR4A2 (0.68) | MRGPRX4PTGER1NR4A2 | |
| SCHEMBL31031135 | 0.88 | MRGPRX4 (0.56) | MRGPRX4PTGER1NR4A2RAB9ANR4A1 | |
| SCHEMBL2744895 | 0.88 | PARP10 (0.59) | MRGPRX4PTGER1LMNAHTTRAB9A | |
| SCHEMBL4747320 | 0.88 | MAOB (0.59) | MRGPRX4PTGER1RAB9AMEN1KMT2A | |
| SCHEMBL5605127 | 0.88 | PTGER1 (0.71) | MRGPRX4PTGER1NR4A2RAB9ANR4A1 | |
| SCHEMBL31197222 | 0.88 | PTGER1 (0.71) | MRGPRX4PTGER1NR4A2RAB9ANR4A1 | |
| SCHEMBL9341900 | 0.87 | NPC1 (0.54) | MRGPRX4PTGER1NR4A2RAB9ANR4A1 | |
| SCHEMBL8512033 | 0.87 | SLC6A2 (0.57) | MRGPRX4PTGER1LMNARAB9AKMT2A | |
| SCHEMBL4161097 | 0.85 | NPC1 (0.53) | MRGPRX4PTGER1RAB9AS1PR5HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5201929-A | — | — | None | — | — | JP | disclosed |
| US-12459891-B2 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | ACCURE THERAPEUTICS, S.L. (ES) | 2025-11-04 | — | — | US | disclosed |
| EP-4178945-B1 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | ACCURE THERAPEUTICS S L (ES) | 2024-08-28 | — | — | EP | disclosed |
| US-20240254135-A1 | POLYPHENOL COMPOUNDS | EPIRIUM BIO INC (US) | 2024-08-01 | — | — | US | disclosed |
| CN-117545738-A | 1- [1- (4-benzyloxy-3, 5-difluoro-benzoyl) -4-fluoro-pyrrolidine-2-carbonyl ] pyrrolidine-2-carbonitrile | 安克瑞治疗公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230250058-A1 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | ACCURE THERAPEUTICS, S.L. (ES) | 2023-08-10 | — | — | US | disclosed |
| EP-4178945-A1 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | Accure Therapeutics, S.L. (ES) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022008477-A1 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | ACCURE THERAPEUTICS, S.L. (ES) | 2022-01-13 | — | — | WO | disclosed |
| US-10611727-B2 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | UNIVERSITAT DE BARCELONA (ES) | 2020-04-07 | — | — | US | disclosed |
| US-10611727-B2 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | UNIVERSITAT DE BARCELONA (ES) | 2020-04-07 | — | — | US | disclosed |
| CN-1918134-A | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
| EP-1699766-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| CN-1747936-A | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA INC (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005061465-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| US-6666989-B1 | Electrical and electro-optic apparatus comprising spaced glass panels having polyethers and electrodes on the interior surfaces, used as detectors, screens and in nonlinear optical apparatus | QINETIQ LIMITED (GB) | 2003-12-23 | — | — | US | disclosed |
| EP-1060226-A1 | LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999043763-A1 | LIQUID CRYSTAL POLYMER DEVICES AND MATERIALS | THE SECRETARY OF STATE FOR DEFENCE (GB) | 1999-09-02 | — | — | WO | disclosed |
| JP-H05201929-A | OPTICALLY ACTIVE COMPOUND AND DISPLAY ELEMENT | MITSUBISHI PETROCHEM CO LTD | 1993-08-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250058-A1 | 1-[1-(4-BENZYLOXY-3,5-DIFLUORO-BENZOYL)-4-FLUORO-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE | BDNF, GRIN2C, GRIN2A | MRGPRX4 4191/4885PTGER1 1460/4885NR4A2 530/4885 |
| US-10611727-B2 | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | BDNF, GRIN1, NLN | MRGPRX4 4144/4885PTGER1 489/4885NR4A2 1145/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | MRGPRX4 2542/4885PTGER1 568/4885NR4A2 296/4885 |
| US-20240254135-A1 | POLYPHENOL COMPOUNDS | COMT, MAPT, PPARG | MRGPRX4 4823/4885PTGER1 2493/4885NR4A2 149/4885 |
| US-12459891-B2 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | BDNF, GRIN2C, GRIN2A | MRGPRX4 4191/4885PTGER1 1460/4885NR4A2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.